Journal Article

Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis

Mahato, Arun Kumar, Wong, Hoi Leong Xavier, Gurung, Susma, Asthana, Pallavi, Kwan, Hiu Yee, Wu, Jiayan, Zhang, Yijing, Bian, Zhao-Xiang, Huang, Jiangang, Ustav, Mart, Xu, Pingyi, Chan, Kui Ming, Guo, Xuanming, Lyu, Aiping, Cheng, Ka Wing, Saarma, Mart, Zhai, Lixiang

2024

Overview

Obesity, a global health challenge, is a major risk factor for multiple life-threatening diseases, including diabetes, fatty liver, and cancer. There is an ongoing need to identify safe and tolerable therapeutics for obesity management. Herein, we show that treatment with artesunate, an artemisinin derivative approved by the FDA for the treatment of severe malaria, effectively reduces body weight and improves metabolic profiles in preclinical models of obesity, including male mice with overnutrition-induced obesity and male cynomolgus macaques with spontaneous obesity, without inducing nausea and malaise. Artesunate promotes weight loss and reduces food intake in obese mice and cynomolgus macaques by increasing circulating levels of Growth Differentiation Factor 15 (GDF15), an appetite-regulating hormone with a brainstem-restricted receptor, the GDNF family receptor α-like (GFRAL). Mechanistically, artesunate induces the expression of GDF15 in multiple organs, especially the liver, in mice through a C/EBP homologous protein (CHOP)-directed integrated stress response. Inhibition of GDF15/GFRAL signalling by genetic ablation of GFRAL or tissue-specific knockdown of GDF15 abrogates the anti-obesity effect of artesunate in mice with diet-induced obesity, suggesting that artesunate controls bodyweight and appetite in a GDF15/GFRAL signalling-dependent manner. These data highlight the therapeutic benefits of artesunate in the treatment of obesity and related comorbidities. Obesity is a global health challenge with an ongoing need for new medical treatments. Here, the authors show that artesunate, an FDA-approved treatment for severe malaria, can be repurposed for the treatment of obesity via GDF15/GFRAL signaling axis without overt side effects in mice and non-human primates.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 13/1 / 13/109 / 13/51 / 14/19 / 38/109 / 38/39 / 38/44 / 38/77 / 38/88 / 38/89 / 631/154/555 / 631/443/319/1642/393 / 692/163/2743/393 / 82/80 / Ablation / Animal models / Appetite / Artemisinin / Artesunate / Body weight / Body weight loss / Brain stem / CCAAT/enhancer-binding protein / Cellular stress response / Comorbidity / Diabetes mellitus / Fatty liver / Food intake / Glial cell line-derived neurotrophic factor / Global health / Health services / Humanities and Social Sciences / Liver / Liver cancer / Malaria / Males / Medical treatment / multidisciplinary / Obesity / Overnutrition / Primates / Public health / Receptors / Risk factors / Science / Science (multidisciplinary) / Side effects / Vector-borne diseases / Weight control / Weight loss / Weight reduction